Pooled safety summary for patients treated with the CD22-directed cytotoxin moxetumomab pasudotox-tdfk.

7014Background: Moxetumomab pasudotox-tdfk was FDA-approved in 2018 for the treatment of adults with relapsed/refractory hairy cell leukemia (HCL) who have received ≥2 prior therapies, including a ...